Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)-Reference-Cited by-同舟云学术

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

Published:2023-11-02 Issue:12 Volume:12 Page:2691-2707
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Kijak Gustavo H.,Ahani Bahar,Arbetter Douglas,Chuecos Fernando,Gopalakrishnan Vancheswaran,Beloor Jagadish,Brady Tyler,Nguyen Amy,Roe Tiffany L.,Schuko Nicolette,Zhang Tianhui,Hobbs F. D. Richard,Padilla Francisco,Kelly Elizabeth J.,Montgomery Hugh,Streicher Katie

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-023-00882-2.pdf

Reference36 articles.

1. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–302. https://doi.org/10.1016/S1473-3099(22)00320-6.

2. Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis. 2022;81(5):687–94. https://doi.org/10.1136/annrheumdis-2021-221558.

3. Manothummetha K, Chuleerarux N, Sanguankeo A, et al. Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(4):e226822. https://doi.org/10.1001/jamanetworkopen.2022.6822.

4. Re D, Seitz-Polski B, Brglez V, et al. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat Commun. 2022;13(1):864. https://doi.org/10.1038/s41467-022-28578-0.

5. Marlet J, Gatault P, Maakaroun Z, et al. Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia. Vaccines. 2021;9(10):1055. https://doi.org/10.3390/vaccines9101055.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab;Future Virology;2024-03-23